SBIR/STTR Research Award
High Z Oraya Therapy for wet AMD
Award amount
$215,200Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ORAYA THERAPEUTICS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-089
- Topic code
- NEI
Research abstract
Project Description The purpose of this project is to develop a new radiotherapy treatment modality that will substantially enhance the treatment of wet AMD with minimal toxicity to healthy tissue, leading to major improvement in visual acuity, decreaseduse of intravitreal injections of anti-VEGF agents, lower cost of treatment, and a substantially improved quality of life for patients. The new modality entitled Customizable Radiotherapy Enhancement (CuRE) using gold nanoparticles will enable major highly localized amplification of radiation damage to the neovascular AMD disease cells with minimal normal ocular tissue toxicity. In order to accomplish this, a potent amount of gold nanoparticles (AuNP), acting as smart bombs will be targeted specificallyto the neovascular AMD (disease) endothelial cells (ECs) as demonstrated in published simulations by Harvard Medical School project partner. Once the AuNP home on to the disease ECs, a relatively small amount of radiation will be focused on the AuNP. The
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Humidifeye Plug for Dry Eye Disease
- A Novel Therapeutic to Promote Corneal Repair
- Drug Screening Platform in the Light-Responsive Human Eye
- RetiVue EntireEye - A Handheld, High-Resolution, Non-Contact, One Image, Widefield Retinal Screening Camera for Premature and Healthy Newborn Babies
- The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence